These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 16359376

  • 1. Mycophenolic acid clinical pharmacokinetics influenced by a cyclosporine C2 based immunosuppressive regimen in renal allograft recipients.
    Mandla R, Midtvedt K, Line PD, Hartmann A, Bergan S.
    Transpl Int; 2006 Jan; 19(1):44-53. PubMed ID: 16359376
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic.
    Brunet M, Crespo M, Millán O, Serón D, Torregrosa V, Jiménez O, Moreso F, Martorell J, Grinyo JM, Oppenheimer F.
    Transplant Proc; 2007 Sep; 39(7):2160-2. PubMed ID: 17889124
    [Abstract] [Full Text] [Related]

  • 3. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Majchrnak J, Gralak B.
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [Abstract] [Full Text] [Related]

  • 4. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 5. Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation.
    Mino Y, Naito T, Matsushita T, Otsuka A, Ushiyama T, Ozono S, Hishida A, Kagawa Y, Kawakami J.
    Ther Drug Monit; 2008 Dec; 30(6):656-61. PubMed ID: 18978521
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and ACYl glucuronide metabolites in stable thoracic transplant recipients.
    Ting LS, Partovi N, Levy RD, Riggs KW, Ensom MH.
    Ther Drug Monit; 2008 Jun; 30(3):282-91. PubMed ID: 18520599
    [Abstract] [Full Text] [Related]

  • 7. Impact of calcineurin inhibitors on urinary excretion of mycophenolic acid and its glucuronide in kidney transplant recipients.
    Naito T, Mino Y, Otsuka A, Ushiyama T, Ito T, Ozono S, Kagawa Y, Kawakami J.
    J Clin Pharmacol; 2009 Jun; 49(6):710-8. PubMed ID: 19451405
    [Abstract] [Full Text] [Related]

  • 8. Cyclosporine alters correlation between free and total mycophenolic acid in kidney transplant recipients in the initial phase.
    Mino Y, Naito T, Otsuka A, Takayama T, Ozono S, Kagawa Y, Kawakami J.
    J Clin Pharm Ther; 2011 Apr; 36(2):217-24. PubMed ID: 21366651
    [Abstract] [Full Text] [Related]

  • 9. Trough levels of mycophenolic acid and its glucuronidated metabolite in renal transplant recipients.
    Merkel U, Lindner S, Vollandt R, Sperschneider H, Balogh A.
    Int J Clin Pharmacol Ther; 2005 Aug; 43(8):379-88. PubMed ID: 16119513
    [Abstract] [Full Text] [Related]

  • 10. Chronopharmacokinetics of mycophenolic acid and its glucuronide and acyl glucuronide metabolites in kidney transplant recipients converted from cyclosporine to everolimus.
    Tedesco-Silva H, Felipe CR, Slade A, Schmouder RL, Medina Pestana JO.
    Ther Drug Monit; 2012 Dec; 34(6):652-9. PubMed ID: 23131696
    [Abstract] [Full Text] [Related]

  • 11. Abbreviated AUC monitoring of cyclosporine more adequately identified patients at risk for acute rejection during induction of immunosuppressive therapy after kidney transplantation than recommended C2 concentration values.
    Troncoso P, Ortiz AM, Jara A, Vilches S.
    Transplant Proc; 2009 Dec; 41(1):127-30. PubMed ID: 19249495
    [Abstract] [Full Text] [Related]

  • 12. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients.
    Akhlaghi F, Gonzalez L, Trull AK.
    J Heart Lung Transplant; 2005 Dec; 24(12):2120-8. PubMed ID: 16364860
    [Abstract] [Full Text] [Related]

  • 13. Concentrations of mycophenolic acid and glucuronide metabolites under concomitant therapy with cyclosporine or tacrolimus.
    Patel CG, Harmon M, Gohh RY, Akhlaghi F.
    Ther Drug Monit; 2007 Feb; 29(1):87-95. PubMed ID: 17304155
    [Abstract] [Full Text] [Related]

  • 14. Inadequate mycophenolic acid exposure and acute rejection in kidney transplantation.
    Sánchez-Fructuoso AI, de la Higuera MA, Giorgi M, Ramos F, Garcia Ledesma P, Calvo N, Pérez-Flores I, Barrientos A.
    Transplant Proc; 2009 Feb; 41(6):2104-5. PubMed ID: 19715844
    [Abstract] [Full Text] [Related]

  • 15. Pharmacodynamic monitoring of the conversion of cyclosporine to tacrolimus in heart and lung transplant recipients.
    Barten MJ, Rahmel A, Garbade J, Bold A, Bittner HB, Dhein S, Mohr FW, Gummert JF.
    Transplant Proc; 2005 Dec; 37(10):4532-4. PubMed ID: 16387162
    [Abstract] [Full Text] [Related]

  • 16. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
    Rodríguez E, Delucchi MA, Cano F, Valdebenito S, Castillo MC, Villegas R.
    Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
    [Abstract] [Full Text] [Related]

  • 17. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation.
    Opelz G, Döhler B, Collaborative Transplant Study.
    Transplantation; 2009 Mar 27; 87(6):795-802. PubMed ID: 19300179
    [Abstract] [Full Text] [Related]

  • 18. Analysis of liver function in renal transplant recipients undergoing C2-monitoring for cyclosporine.
    Hecking M, Kainz A, Schillinger M, Posch C, Birsan T, Rasoul-Rockenschaub S, Böhmig GA, Schmaldienst S, Watschinger B, Hörl WH, Mühlbacher F, Säemann MD.
    Transpl Int; 2008 Mar 27; 21(3):223-33. PubMed ID: 17903183
    [Abstract] [Full Text] [Related]

  • 19. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
    Büchler M, Chadban S, Cole E, Midtvedt K, Thervet E, Prestele H, Keown P.
    Nephrol Dial Transplant; 2006 Jan 27; 21(1):197-202. PubMed ID: 16204301
    [Abstract] [Full Text] [Related]

  • 20. Effect of cyclosporine on steady-state pharmacokinetics of MPA in renal transplant recipients is not affected by the MPA formulation: analysis based on therapeutic drug monitoring data.
    Trkulja V, Lalić Z, Nađ-Škegro S, Lebo A, Granić P, Lovrić M, Pasini J, Božina N.
    Ther Drug Monit; 2014 Aug 27; 36(4):456-64. PubMed ID: 24518562
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.